Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
FBTIX vs BIB
Shared holdings
50
FBTIX covered by BIB
25.93%
BIB covered by FBTIX
25.93%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
FBTIX (Jan. 31, 2026)
| Security | Weight | |
|---|---|---|
| ABBVIE INC | 16.04% | |
| GILEAD SCIENCES INC | 6.35% | |
| ALNYLAM PHARMACEUTICALS INC | 4.85% | |
| Ascendis Pharma A/S | 4.34% | |
| COGENT BIOSCIENCES INC | 3.70% | |
| ARGENX SE SPONSORED ADR | 3.52% | |
| Fidelity Securities Lending Cash Central Fund | 3.47% | |
| INSMED INC | 3.35% | |
| VIRIDIAN THERAPEUTICS INC | 3.05% | |
| BIOGEN INC | 2.74% | |
| AMGEN INC | 2.67% | |
| VAXCYTE INC | 2.21% | |
| STRUCTURE THERAPEUTICS INC ADR | 2.20% | |
| NUVALENT INC-A | 2.20% | |
| DIANTHUS THERAPEUTICS INC | 2.02% | |
| AMYLYX PHARMACEUTICALS INC | 1.80% | |
| MODERNA INC | 1.54% | |
| APOGEE THERAPEUTICS INC | 1.54% | |
| XENON PHARMACEUTICALS INC | 1.51% | |
| CRINETICS PHARMACEUTICALS INC | 1.41% | |
| PRAXIS PRECISION MEDICINES INC | 1.40% | |
| SCHOLAR ROCK HOLDING CORP | 1.34% | |
| ORUKA THERAPEUTICS INC | 1.26% | |
| SPYRE THERAPEUTICS INC | 1.24% | |
| UCB SA | 1.19% | |
| UNIQURE N.V. | 1.17% | |
| UPSTREAM BIO INC | 1.11% | |
| ROIVANT SCIENCES LTD | 1.09% | |
| NATERA INC | 1.07% | |
| OLEMA PHARMACEUTICALS INC | 1.04% | |
| VIKING THERAPEUTICS INC | 0.97% | |
| NEWAMSTERDAM PHARMA COMPANY NV | 0.94% | |
| CYTOKINETICS INC | 0.93% | |
| KYMERA THERAPEUTICS INC | 0.87% | |
| JADE BIOSCIENCES INC | 0.72% | |
| CG ONCOLOGY INC | 0.67% | |
| RHYTHM PHARMACEUTICALS INC | 0.67% | |
| ENLIVEN THERAPEUTICS INC | 0.65% | |
| ZENAS BIOPHARMA INC | 0.60% | |
| DISC MEDICINE INC | 0.57% | |
| ARCELLX INC | 0.51% | |
| STOKE THERAPEUTICS INC | 0.50% | |
| SONOMA BIOTHERAPEUTICS INC SER B PFD PP | 0.49% | |
| TRAVERE THERAPEUTICS INC | 0.48% | |
| MINERALYS THERAPEUTICS INC | 0.43% | |
| CYTOMX THERAPEUTICS INC | 0.40% | |
| ANAPTYSBIO INC | 0.36% | |
| SOLENO THERAPEUTICS INC | 0.36% | |
| CELLDEX THERAPEUTICS INC | 0.35% | |
| REZOLUTE INC | 0.34% |
BIB (Feb. 28, 2026)
| Security | Weight | |
|---|---|---|
| US ULTRA BOND CBT Sep25 | 19.64% | |
| GILEAD SCIENCES INC | 6.95% | |
| VERTEX PHARMACEUTICALS INC | 6.72% | |
| AMGEN INC | 6.59% | |
| Repurchase Agreement | 6.10% | |
| REGENERON PHARMACEUTICALS INC | 4.36% | |
| ALNYLAM PHARMACEUTICALS INC | 2.37% | |
| Invesco Government & Agency Portfolio, Institutional Class | 1.94% | |
| INSMED INC | 1.72% | |
| BIOGEN INC | 1.52% | |
| ARGENX SE SPONSORED ADR | 1.20% | |
| UNITED THERAPEUTICS CORP DEL | 1.17% | |
| MODERNA INC | 1.13% | |
| ILLUMINA INC | 1.11% | |
| ROIVANT SCIENCES LTD | 1.09% | |
| INCYTE CORP | 1.07% | |
| ROYALTY PHARMA PLC | 1.07% | |
| REVOLUTION MEDICINES INC | 1.06% | |
| VIATRIS INC | 0.93% | |
| Ascendis Pharma A/S | 0.77% | |
| NEUROCRINE BIOSCIENCES INC | 0.71% | |
| IONIS PHARMACEUTICALS INC | 0.71% | |
| SANOFI SPON ADR | 0.69% | |
| BRIDGEBIO PHARMA INC | 0.69% | |
| MEDPACE HOLDINGS INC | 0.69% | |
| SUMMIT THERAPEUTICS INC | 0.67% | |
| GUARDANT HEALTH INC | 0.66% | |
| BIOMARIN PHARMACEUTICAL INC | 0.64% | |
| EXELIXIS INC | 0.64% | |
| JAZZ PHARMA PLC | 0.62% | |
| BIONTECH SE ADR | 0.60% | |
| BEONE MEDICINES LTD ADR | 0.54% | |
| MADRIGAL PHARMACEUTICALS INC | 0.53% | |
| IMMUNITYBIO INC | 0.52% | |
| TEMPUS AI INC-A | 0.50% | |
| ARROWHEAD PHARMACEUTICALS INC | 0.46% | |
| PRAXIS PRECISION MEDICINES INC | 0.45% | |
| AXSOME THERAPEUTICS INC | 0.45% | |
| HALOZYME THERAPEUTICS INC | 0.44% | |
| VAXCYTE INC | 0.44% | |
| KRYSTAL BIOTECH INC | 0.43% | |
| CYTOKINETICS INC | 0.41% | |
| NUVALENT INC-A | 0.40% | |
| Abivax SA SPONSORED ADS | 0.39% | |
| ARCELLX INC | 0.36% | |
| KYMERA THERAPEUTICS INC | 0.35% | |
| RHYTHM PHARMACEUTICALS INC | 0.33% | |
| COGENT BIOSCIENCES INC | 0.32% | |
| PROTAGONIST THERAPEUTICS INC | 0.31% | |
| CRISPR THERAPEUTICS AG | 0.31% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.